SYDNEY-BASED Pacific Equity Partners (PEP) together with global investment company The Carlyle Group won what has become a virtual six-month auction process to purchase pharmaceutical company iNova from US-listed Valeant Pharmaceuticals for US$930m (AU$1.23b).
Carlyle md David Bluff said that iNova was a strong company with great products and growth opportunities and private investors would look to grow iNova's footprint.
PEP md David Brown said the plan was to build on iNova's broadly diversified healthcare platform by investment in "product development, geographical expansion, marketing, staff and potential acquisitions of additional brands".
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Jun 17
